PubMed Health⌕ Search

Biomedical subjects

Claudia Wild

Publications and source records attributed to Claudia Wild.

6 recordsLinked to original sources

Evaluating and planning ICUs: methods and approaches to differentiate between need and demand.

OBJECTIVE: In all western countries the demand for ICU-services is increasing and complaints about a lack of ICU-beds arise--independent of the actual density of ICU-services. The demand for more ICU-beds triggered a debate on whether it is possible to define an "objective" need. It was the aim of the assessment to analyze conventional as well as innovative approaches to plan and to evaluate ICU-services. METHOD: Systematic review, multistep searches in Medline, EmBase, Cochrane, HTA-Database, websearches, informal searches through planning and HTA-networks. INTRODUCTION: The differences between the density of intensive care in Europe and other parts of the western world is enormous. At a first superficial glance, Austria and Germany--in absolute figures--have many more ICU-beds than any other European country. In relative figures, taken into consideration that Austria and Germany have also many more acute care beds, the number of ICU-beds is among European average. It is therefore, impossible to analyze the need for ICU-beds without taking into account the national context of delivered acute hospital services. Although ICU-services take about 15-20% of the hospital budgets, there are still more questions than answers. RESULTS: Recent planning-documents: a review of trends in recent planning shows that all planners calculate on the basis of existing style of practice within their countries; the figures change only marginally. But while planners in countries with a relatively low ICU-bed density (Great Britan, Australia, Canada) certify a certain need for an increase, planners in countries with high density (USA, Germany, Austria) state a "satisfied need" and an over-provision of ICU-services. Innovative planners apply an "appropriateness of ICU-use" approach with analysing the actual utilisation by interpreting scores (especially TISS) and by identifying "low-risk" groups and propose a more flexible organisation of ICUs and a higher proportion of (intermediate care unit) IMCU-beds. Clinical and ICU-management tools, such as admission and discharge guidelines, strategies to reduce treatment-variations, certain organisational changes (leadership, horizontal hierarchy) and costing methods gain importance for better, more efficient and co-ordinated use of ICU-resources. CONCLUSION: In countries with a high density of ICU-services--such as Austria and Germany--not an expanding of the capacities, but a better use of the existing resources is recommended. For a fair comparison, participation in national databases, in registers as well as benchmarking and quality-assurance programs should be enforced.

Benchmarking↗

L-type Ca2+ channels in Ca2+ channelopathies.

Voltage-gated L-type Ca2+ channels (LTCCs) mediate depolarization-induced Ca2+ entry in electrically excitable cells, including muscle cells, neurons, and endocrine and sensory cells. In this review we summarize the role of LTCCs for human diseases caused by genetic Ca2+ channel defects (channelopathies). LTCC dysfunction can result from structural aberrations within pore-forming alpha1 subunits causing incomplete congenital stationary night blindness, malignant hyperthermia sensitivity or hypokalemic periodic paralysis. However, studies in mice revealed that LTCC dysfunction also contributes to neurological symptoms in Ca2+ channelopathies affecting non-LTCCs, such as Ca(v)2.1 alpha1 in tottering mice. Ca2+ channelopathies provide exciting molecular tools to elucidate the contribution of different LTCC isoforms to human diseases.

Animals↗

Evaluations of health interventions in social insurance-based countries: Germany, the Netherlands, and Austria.

Health Technology Assessment (HTA) in social insurance-based, or so-called 'Bismarck' health care systems (Germany, Austria, and the Netherlands) has taken a different course than in either taxed-based (Sweden, Norway, United Kingdom, and Spain) or private health care systems (such as the United States). The culture of informed decisions supported by transparent and evidence-based evaluations of health interventions was hindered by the strong professional autonomy and sectoral interests in Germany and Austria for a long time. On the other hand, HTA has a long-standing tradition in the Netherlands. In all three countries sickness funds play an important role in implementing evaluations-as a policy tool-by linking reimbursement to explicit proof of effectiveness in both new and established interventions. This article focuses on the obstacles and opportunities for HTA in Germany, Austria and the Netherlands as countries with insurance-based health care systems.

Austria↗

Physarum polycephalum expresses a dihydropteridine reductase with selectivity for pterin substrates with a 6-(1', 2'-dihydroxypropyl) substitution.

Physarum polycephalum is one of few non-animal organisms capable of synthesizing tetrahydrobiopterin from GTP. Here we demonstrate developmentally regulated expression of quinoid dihydropteridine reductase (EC 1.6.99.7), an enzyme required for recycling 6,7-[8H]-dihydrobiopterin. Physarum also expresses phenylalanine-4-hydroxylase activity, an enzyme that depends on dihydropteridine reductase. The 24.4 kDa Physarum dihydropteridine reductase shares 43% amino acid identity with the human protein. A number of residues important for function of the mammalian enzyme are also conserved in the Physarum sequence. In comparison to sheep liver dihydropteridine reductase, purified recombinant Physarum dihydropteridine reductase prefers pterin substrates with a 6-(1', 2'-dihydroxypropyl) group. Our results demonstrate that Physarum synthesizes, utilizes and metabolizes tetrahydrobiopterin in a way hitherto thought to be restricted to the animal kingdom.

Amino Acid Sequence↗

["Screening" in special situations. Assessing predictive genetic screening for hereditary breast and colorectal cancer].

AIMS AND METHODS: The aim of this health technology assessment was to analyse the current scientific and genetic counselling on predictive genetic testing for hereditary breast and colorectal cancer. Predictive genetic testing will be available for several common diseases in the future and questions related to financial issues and quality standards will be raised. This report is based on a systematic/nonsystematic literature search in several databases (e.g. EmBase, Medline, Cochrane Library) and on a specific health technology assessment report (CCOHTA) and review (American Gastroenterological Ass.), respectively. Laboratory test methods, early detection methods and the benefit from prophylactic interventions were analysed and social consequences interpreted. BACKGROUND: Breast and colorectal cancer are counted among the most frequently cancer diseases. Most of them are based on random accumulation of risk factors, 5-10% show a familial determination. A hereditary modified gene is responsible for the increased cancer risk. In these families, high tumour frequency, young age at diagnosis and multiple primary tumours are remarkable. RESULTS AND REFLECTION: GENETIC DIAGNOSIS: Sequence analysis is the gold standard. Denaturing high performance liquid chromatography is a quick alternative method. The identification of the responsible gene defect in an affected family member is important. If the test result is positive there is an uncertainty whether the disease will develop or not, when and in which degree, which is founded in the geno-/phenotype correlation. The individual risk estimation is based upon empirical evidence. The test results affect the whole family. PREVENTION/EARLY DETECTION: Currently, primary prevention is possible for familial adenomatous polyposis (celecoxib, prophylactic colectomy) and for hereditary mamma carcinoma (prophylactic mastectomy). The so-called preventive medical check-ups are early detection examinations. The evidence about early detection methods for colorectal cancer is better than for breast cancer. PROPHYLACTIC SURGICAL INTERVENTIONS: Prophylactic mastectomy (PM) reduces the relative breast cancer risk by approximately 90%. The question is if PM has an impact on mortality. The acceptance of PM is culture-dependent. Colectomy can be used as a prophylactic (FAP) and therapeutic method. After surgery, the cancer risk remains high and so early detection examinations are still necessary. EVIDENCE-BASED STATEMENTS: The evidence is often fragmentary and of limited quality. For objective test result presentation information about sensitivity, specificity, positive predictive value, and number needed to screen and treat, respectively, are necessary. REFLECTIONS: New identification of mutations and demand will lead to an increase of predictive genetic counselling and testing. There is a gap between predictive genetic diagnosis and prediction, prevention, early detection and surgical interventions. These circumstances require a basic strategy. Since predictive genetic diagnosis is a very sensitive issue it is important to deal with it carefully in order to avoid inappropriate hopes. Thus, media, experts and politicians need to consider opportunities and limitations in their daily decision-making processes.

Breast Neoplasms↗